Monte Rosa Therapeutics Inc (GLUE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $800.67M
Last updated: Nov 17, 2026 at 11:05 AM ET
Monte Rosa Therapeutics Inc (GLUE) Stock Forecast
Analysts expect Monte Rosa Therapeutics (GLUE) to earn -$1.02 per share in the fiscal year ending Dec 31, 2026, on revenue of $102.27M. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 20.0% |
| Buy | 8 | 80.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 39.2%.
- Fiscal year ending Dec 31, 2026
- -$1.02
- EPS consensus, revenue $102.27M
- Fiscal year ending Dec 31, 2027
- -$1.78
- EPS consensus, revenue $62.16M
- Next report
- Mar 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.02 | -$1.40 to -$0.28 | 7 | $102.27M | $67.50M to $190.85M | 8 |
| Dec 31, 2027 | -$1.78 | -$3.15 to $0.37 | 8 | $62.16M | N/A | 9 |
Quarterly Estimates
The EPS consensus falls from -$0.30 for the quarter ending Dec 31, 2026 to -$0.46 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.30 | -$0.57 to -$0.08 | 11 | $27.45M | N/A | 11 |
| Mar 31, 2027 | -$0.46 | -$0.73 to $0.06 | 5 | $3.92M | N/A | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 1 |
| Fiscal year ending Dec 31, 2027 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.57.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.02 | -$1.37 | -$1.43 | -$1.57 | -$1.57 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.78 | -$1.84 | -$1.95 | -$1.88 | -$1.88 | N/A |
| Quarter ending Mar 31, 2027 | -$0.46 | -$0.59 | -$0.60 | -$0.61 | -$0.61 | N/A |
Frequently Asked Questions About GLUE
What is the GLUE stock forecast?
Consensus analyst estimates put Monte Rosa Therapeutics's EPS at -$1.02 for the fiscal year ending Dec 31, 2026, on revenue of $102.27M. The consensus rating from 10 analysts is Buy.
How do analysts rate GLUE stock?
Of 10 analysts covering Monte Rosa Therapeutics, 2 rate it Strong Buy, 8 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from GLUE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.02, with estimates from -$1.40 to -$0.28 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.78, with estimates from -$3.15 to $0.37 from 8 analysts.
What revenue do analysts expect from Monte Rosa Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $102.27M, with estimates from $67.50M to $190.85M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $62.16M.
How many analysts cover GLUE?
10 analysts rate Monte Rosa Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
GLUE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors